Rempex Drug Patent Portfolio

Rempex owns 2 orange book drugs protected by 14 US patents Given below is the list of Rempex's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12533342 20 May, 2039
Active
US11376237 Methods of treating bacterial infections 06 Apr, 2039
Active
US12478606 Methods Of Treating Bacterial Infections 08 Jan, 2038
Active
US11944634 Tetracycline compositions 16 Oct, 2032
Active
US8680136 Cyclic boronic acid ester derivatives and therapeutic uses thereof 29 Aug, 2031
Active
US10172874 Pharmaceutical compositions comprising cyclic boronic acid ester derivatives 08 Aug, 2031
Active
US10183034 Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives 08 Aug, 2031
Active
US10561675 Cyclic boronic acid ester derivatives and therapeutic uses thereof 08 Aug, 2031
Active
US11007206 Cyclic boronic acid ester derivatives and therapeutic uses thereof 08 Aug, 2031
Active
US12171772 Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives 08 Aug, 2031
Active
US9694025 Cyclic boronic acid ester derivatives and therapeutic uses thereof 08 Aug, 2031
Active
US12161656 Tetracycline compositions 12 May, 2031
Active
US9084802 Tetracycline compositions 12 May, 2031
Active
US9278105 Tetracycline compositions 12 May, 2031
Active


Given below is the list of recent legal activities going on the following drug patents of Rempex.

Activity Date Patent Number
Patent litigations
Information Disclosure Statement (IDS) Filed 18 Sep, 2025 US12478606
Mail Notice of Allowance 18 Sep, 2025 US12533342
Notice of Allowance Data Verification Completed 17 Sep, 2025 US12533342
Mail PUB other miscellaneous communication to applicant 03 Sep, 2025 US12478606
Email Notification 03 Sep, 2025 US12478606
PUB Other miscellaneous communication to applicant 02 Sep, 2025 US12478606
PARALEGAL OR ELECTRONIC TERMINAL DISCLAIMER APPROVED 11 Aug, 2025 US12533342
Date Forwarded to Examiner 10 Aug, 2025 US12533342
Email Notification 06 Aug, 2025 US12533342
Change in Power of Attorney (May Include Associate POA) 06 Aug, 2025 US12533342
Response after Non-Final Action 04 Aug, 2025 US12533342
Terminal Disclaimer Filed 04 Aug, 2025 US12533342
Information Disclosure Statement considered 16 Jul, 2025 US12478606
Printer Rush- No mailing 16 Jul, 2025 US12478606
Pubs Case Remand to TC 15 Jul, 2025 US12478606


Rempex's Drug Patent Litigations

Rempex's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 25, 2016, against patent number US10561675. The petitioner , challenged the validity of this patent, with Rempex Pharmaceuticals, Inc. as the respondent. Click below to track the latest information on how companies are challenging Rempex's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10561675 November, 2016 Decision
(28 Aug, 2018)
Rempex Pharmaceuticals, Inc.


Rempex's Family Patents

Rempex drugs have patent protection in a total of 32 countries. It's US patent count contributes only to 28.3% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Rempex Drug List

Given below is the complete list of Rempex's drugs and the patents protecting them.


1. Minocin

Minocin is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11944634 Tetracycline compositions 16 Oct, 2032
(6 years from now)
Active
US12161656 Tetracycline compositions 12 May, 2031
(5 years from now)
Active
US9084802 Tetracycline compositions 12 May, 2031
(5 years from now)
Active
US9278105 Tetracycline compositions 12 May, 2031
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Minocin's drug page


2. Vabomere

Vabomere is protected by 10 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12533342 20 May, 2039
(13 years from now)
Active
US11376237 Methods of treating bacterial infections 06 Apr, 2039
(13 years from now)
Active
US12478606 Methods Of Treating Bacterial Infections 08 Jan, 2038
(11 years from now)
Active
US8680136 Cyclic boronic acid ester derivatives and therapeutic uses thereof 29 Aug, 2031
(5 years from now)
Active
US10172874 Pharmaceutical compositions comprising cyclic boronic acid ester derivatives 08 Aug, 2031
(5 years from now)
Active
US10183034 Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives 08 Aug, 2031
(5 years from now)
Active
US10561675 Cyclic boronic acid ester derivatives and therapeutic uses thereof 08 Aug, 2031
(5 years from now)
Active
US11007206 Cyclic boronic acid ester derivatives and therapeutic uses thereof 08 Aug, 2031
(5 years from now)
Active
US12171772 Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives 08 Aug, 2031
(5 years from now)
Active
US9694025 Cyclic boronic acid ester derivatives and therapeutic uses thereof 08 Aug, 2031
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vabomere's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List